$Analysis of relapsed/refractory Hodgkin lymphoma treated with autologous transplantation: A single-center experience$

Analysis of relapsed/refractory Hodgkin lymphoma treated with autologous transplantation: A single-center experience

Introduction: Hodgkin lymphoma (HL) is one of the common lymphomas with high cure rate. Aims: The aim was to study the outcome of relapsed/refractory HL treated with autologous transplantation. Objectives: The objective was to study the overall survival, overall response, and disease-free survival o...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vishal Kulkarni, Sulav Sapkota, Girish V Badarkhe, B J Srinivas, Radheshyam Naik
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2020-01-01
Series:	Indian Journal of Medical and Paediatric Oncology
Subjects:	autologous hodgkin refractory relapsed
Online Access:	http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=1;spage=23;epage=28;aulast=Kulkarni
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma
by: Shiliang Ge, et al.
Published: (2025-02-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis
by: Mohamed Nazem Alibrahim, et al.
Published: (2025-05-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

The optimal time for autologous hematopoietic progenitor cell transplantation during treatment of Hodgkin's lymphoma. Foreign recommendations and russian experience
by: N. V. Zhukov, et al.
Published: (2014-09-01)

The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice.
by: I. A. Kamaeva, et al.
Published: (2021-06-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
by: Hongjuan Dong, et al.
Published: (2025-07-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck
by: Dennis Christoph Harrer, et al.
Published: (2025-03-01)

The efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with Non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma who failed mobilization with granulocyte-colony-stimulating factor alone: A single-center experience
by: Girish Badarkhe, et al.
Published: (2020-01-01)

Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study
by: Guang‐Liang Chen, et al.
Published: (2024-08-01)

Impact of Hematopoietic Stem Cell Transplantation on PD-1 Blockade Efficacy in Relapsed/Refractory Hodgkin’s Lymphoma
by: Filomena Emanuela Laddaga, et al.
Published: (2025-04-01)

Combined immunochemotherapy in patients with refractory/relapsed classical Hodgkin's lymphoma as a 2<sup>nd</sup> line treatment before autologous hematopoietic stem cell transplantation (preliminary results)
by: A. A. Mamedova, et al.
Published: (2022-07-01)

Clinical features and outcomes of newly diagnosed classical Hodgkin lymphoma patients in Saudi Arabia: a multicenter cohort study
by: Mai Alalawi, et al.
Published: (2025-05-01)

Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study
by: Ya. V. Krylova, et al.
Published: (2024-09-01)

Immunochemotherapy of refractory classical Hodgkin's lymphoma with high-dose consolidation and autologous hematopoietic stem cell transplantation complicated by a new coronavirus infection
by: L. S. Khayrullina, et al.
Published: (2022-07-01)

Subgroup analysis of treatment pathways and clinical outcomes in Hodgkin lymphoma in Latin America from the retrospective B-HOLISTIC study
by: Alvaro Hernandez-Caballero, et al.
Published: (2025-07-01)

Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study
by: Danyang Li, et al.
Published: (2025-02-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Is Salvage Autologous Stem Cell Transplantation Still a Viable Treatment Option in Relapsed Myeloma Patients?
by: Luka Čemažar, et al.
Published: (2025-05-01)

Autologous stem cell transplantation in the treatment of Hodgkin's disease
by: Tarabar Olivera, et al.
Published: (2009-01-01)

Response Rate After Modified Regime DHAP and Toxicity with Refractory and Relapsed Disease in Lymphoma Patients
by: Reeta Kumari, et al.
Published: (2023-10-01)

PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma
by: EA Demina
Published: (2018-07-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

Outcome of Classical Hodgkin’s Lymphoma Treatment Based on High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation: The Experience in the NI Pirogov Russian National Medical Center of Surgery
by: NE Mochkin, et al.
Published: (2018-07-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children
by: NA Batmanova, et al.
Published: (2017-07-01)

Treatment of pediatric relapsed and refractory acute myeloid leukemia
by: F. A. Makhacheva, et al.
Published: (2023-05-01)

Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01)

Outcome of CBV (Carmustine, Cyclophosphamide, Etoposide) Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma: A Retrospective Study from a Tertiary Cancer Center in South India
by: Narendran Krishnamoorthi, et al.
Published: (2025-02-01)

Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis
by: Magdalena Witkowska, et al.
Published: (2025-01-01)

Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data
by: Ning Lyu, et al.
Published: (2025-01-01)

Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma
by: Yuchen Wu, et al.
Published: (2025-06-01)

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization
by: Phoebe Joy Ho, et al.
Published: (2025-08-01)

EXPERIENCE IN THE TREATMENT OF REFRACTORY HODGKIN’S LYMPHOMA
by: A. M. Chervontseva, et al.
Published: (2021-03-01)

The optimal time for hematopoietic stem cell translantation for Hodgkin's lymphoma. International guidelines and real practic in Russia and former USSSR countries (Part II)
by: N. V. Zhukov, et al.
Published: (2015-01-01)